Bring Your Product to Germany

Market Access
Strategy

Who should pay for your product: patients, statutory health insurances, or private insurers? Together, we will find your way into the German healthcare market.

Explore Our Services Get In Touch

498 bn €

Healthcare Spendings
in Germany
(2022)

90%

of the German Population
in Public Health Insurances

74 m

Insurants in
Public Health
Insurances

9 m

Insurants in
Private Health
Insurances

Our Services

“We were looking for expert guidance on our market access strategy and found it in Digital Oxygen. Together with their network, we could exclude inferior options and swiftly focus on the relevant path to reimbursement.”

Dr. Jannik Lockl

CEO and Co-Founder

Reimbursement

Via this reimbursement path, your healthcare products will be paid for by statutory health insurances (SHI) – with access to more than 74 million insurants.

The German healthcare system offers a wide range of options to get your healthcare product reimbursed by public health insurers – be it pharmaceutical, medtech, digital or physical. More than 90% of German insurants are insured with a public health insurer, 74 million people in total. As attractive as access to this market is, as complex it is: Aside from strict market access regulation and complex admission processes, economic and medical preconditions, a variety of stakeholders have to be taken into account. From health insurers and governing bodies, to prescribers, their team, and their patients. We assess if an SHI reimbursement path is the best choice for your product, define a clear strategy, and are your partners along the reimbursement path.

Out-of-Pocket

Selling your healthcare product as an out-of-pocket offer can be a highly attractive approach – or even the only option if your product is not eligible for reimbursement (yet).

While access to a market of 74 million insurants is certainly attractive, the reimbursement path is not necessarily the best choice for every product – or even an option: For some products, an out-of-pocket strategy might be a much better approach: Be it because of a shorter time-to-market, better pricing options, or simply, because your product does not qualify for the reimbursement path (yet). We assess your market access options, and define your out-of-pocket strategy: From a sound business case to the first-hand validation of your value proposition.

Reimbursement (Private Insurers)

Private health insurances can be strong partners for accessing the German healthcare market.

Ca. 10% of German insurants rely on a private health insurer, that’s round about 9 million people. Compared to statutory health insurances, private health insurers frequently offer their customers a broader range of services, including ones that are not (yet) covered by the statutory providers. For you and your product, reimbursement through private health insurances can be an attractive market access option: Private health insurers are not only more open to innovations, but they also make decisions and take action more quickly and are often more flexible in their requirements and processes.

Spotlight
Publications

Whitepaper: Digital Health Applications (DiGA) in Portugal

25. June 2024

The whitepaper "Digital Health Applications (DiGA) in Portugal," explores the necessity and current status of implementing a DiGA framework in Portugal, offering expert insights and strategic recommendations for enhancing healthcare through digital solutions.

Webinar | Digital Devices in Pediatrics

24. May 2024

Discover the Transformative Reimbursement Pathways in Pediatric Healthcare through Our Engaging Webinar. Learn about the key aspects, benefits, and processes for achieving reimbursement for innovative healthcare solutions.

New Levers in Pharmaceutical Field Force

18. April 2024

The sales force is and remains an essential sales driver for pharmaceutical companies. But not just since the coronavirus has it become clear that the traditional sales force is in urgent need of an update.

Advanced Diabetes Technology Landscape 2024

4. March 2024

The Advanced Diabetes Technology Landscape 2024 is an extensive overview of companies shaping the future of diabetes care.

Whitepaper: HCP Engagement

23. January 2024

The Whitepaper "Enhancing HCP Engagement in Germany" showcases the evolving landscape of HCP engagement, explaining the shift from traditional face-to-face interaction to dynamic digital strategies.